The expression level of the chemerin gene or protein was downregulated in the tissues of patients with hepatocellular carcinoma (HCC) [13], adrenocortical carcinoma [14], melanoma, lung cancer, prostate cancer, and colon cancer [15], and increased expression of chemerin correlated with improved clinical outcomes in patients with HCC, adrenocortical carcinoma, or melanoma. Here, RARRES2 is linked to prostate cancer.